| Date | Time | Source | Headline | Symbol | Company |
| 05/29/2024 | 8:05AM | GlobeNewswire Inc. | Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024 | NASDAQ:ALVO | Alvontech |
| 05/21/2024 | 5:15PM | GlobeNewswire Inc. | Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update | NASDAQ:ALVO | Alvontech |
| 05/21/2024 | 10:05AM | Business Wire | Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK | NASDAQ:ALVO | Alvontech |
| 05/21/2024 | 8:00AM | GlobeNewswire Inc. | Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK | NASDAQ:ALVO | Alvontech |
| 05/21/2024 | 7:13AM | IH Market News | U.S. Index Futures Open Lower Amid Nasdaq Record, Fed Speeches | NASDAQ:ALVO | Alvontech |
| 05/20/2024 | 8:25PM | Business Wire | Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. | NASDAQ:ALVO | Alvontech |
| 05/20/2024 | 8:25PM | GlobeNewswire Inc. | Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. | NASDAQ:ALVO | Alvontech |
| 05/13/2024 | 8:00AM | GlobeNewswire Inc. | Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT) | NASDAQ:ALVO | Alvontech |
| 05/02/2024 | 7:15AM | GlobeNewswire Inc. | Alvotech Announces Participation at BofA Securities Healthcare Conference 2024 | NASDAQ:ALVO | Alvontech |
| 04/30/2024 | 4:00AM | GlobeNewswire Inc. | U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) | NASDAQ:ALVO | Alvontech |
| 04/30/2024 | 4:00AM | Business Wire | U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) | NASDAQ:ALVO | Alvontech |
| 04/24/2024 | 4:00AM | GlobeNewswire Inc. | Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab) | NASDAQ:ALVO | Alvontech |
| 04/19/2024 | 6:10AM | GlobeNewswire Inc. | Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab) | NASDAQ:ALVO | Alvontech |
| 04/16/2024 | 5:43PM | Business Wire | Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) | NASDAQ:ALVO | Alvontech |
| 04/16/2024 | 5:30PM | GlobeNewswire Inc. | Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) | NASDAQ:ALVO | Alvontech |
| 04/03/2024 | 7:41AM | GlobeNewswire Inc. | Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024 | NASDAQ:ALVO | Alvontech |
| 03/22/2024 | 4:15PM | GlobeNewswire Inc. | Alvotech Announces Increase in Number of Own Shares | NASDAQ:ALVO | Alvontech |
| 03/20/2024 | 4:15PM | GlobeNewswire Inc. | Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update | NASDAQ:ALVO | Alvontech |
| 03/20/2024 | 7:17AM | IH Market News | U.S. Index Futures Trade Sideways Amid Anticipation of Fed’s Policy Update; Oil Prices Dip | NASDAQ:ALVO | Alvontech |
| 03/05/2024 | 4:00PM | GlobeNewswire Inc. | Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET | NASDAQ:ALVO | Alvontech |
| 02/29/2024 | 4:05PM | GlobeNewswire Inc. | Alvotech Appoints Interim Chief Quality Officer | NASDAQ:ALVO | Alvontech |
| 02/26/2024 | 4:25AM | GlobeNewswire Inc. | Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share | NASDAQ:ALVO | Alvontech |
| 02/23/2024 | 8:15PM | GlobeNewswire Inc. | Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira® | NASDAQ:ALVO | Alvontech |
| 02/23/2024 | 8:15PM | Business Wire | Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira® | NASDAQ:ALVO | Alvontech |
| 02/15/2024 | 6:30AM | GlobeNewswire Inc. | Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab) | NASDAQ:ALVO | Alvontech |
| 01/29/2024 | 4:00AM | GlobeNewswire Inc. | Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva® | NASDAQ:ALVO | Alvontech |
| 01/19/2024 | 12:31PM | Dow Jones News | Alvotech Shares Climb After FDA Concludes Facility Inspection | NASDAQ:ALVO | Alvontech |
| 01/19/2024 | 11:30AM | GlobeNewswire Inc. | Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04 | NASDAQ:ALVO | Alvontech |
| 01/10/2024 | 3:30AM | GlobeNewswire Inc. | STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara | NASDAQ:ALVO | Alvontech |
| 01/03/2024 | 3:30AM | GlobeNewswire Inc. | Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept) | NASDAQ:ALVO | Alvontech |